行情

SGEN

SGEN

Seattle Genetics
NASDAQ

实时行情|Nasdaq Last Sale

112.93
+2.50
+2.26%
盘后: 112.93 0 0.00% 17:29 01/28 EST
开盘
111.71
昨收
110.43
最高
113.33
最低
110.69
成交量
84.20万
成交额
--
52周最高
122.36
52周最低
62.90
市值
193.55亿
市盈率(TTM)
-60.4453
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SGEN 新闻

  • Benzinga's Top Upgrades, Downgrades For January 28, 2020
  • Benzinga.16小时前
  • BMO likes Seattle Genetics in premarket analyst action
  • Seeking Alpha - Article.18小时前
  • BMO Capital Initiates Coverage On Seattle Genetics with Outperform Rating, Announces $139 Price Target
  • Benzinga.18小时前
  • Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
  • Zacks.01/21 23:13

更多

所属板块

生物技术和医学研究
+0.97%
制药与医学研究
+0.58%

热门股票

名称
价格
涨跌幅

SGEN 简况

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
展开

Webull提供Seattle Genetics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。